Disease State: Stroke Prevention in Atrial Fibrillation (SPAF)

Educational Objectives

1. Highlight the under- recognized risk of stroke and/or  inadequate prophylaxis in patients   with atrial fibrillation and the associated morbidity, mortality, and cost burdens.
2. Discuss strategies to incorporate clinical guidelines and quality measures into patient care to optimize outcomes of anticoagulation therapy.
3. Discuss current and potential new challenges and opportunities in stroke prevention in atrial fibrillation.
4. Describe the multifaceted role of thrombin and its contribution to the underlying pathophysiology that results in thromboembolic events.
5. Enhance awareness and knowledge of current clinical and pharmacoeconomic research that adds to the body of scientific evidence and contributes to the care of patients with atrial fibrillation.
6. Develop strategies to improve communication between HCPs  and their patients/caregivers about the benefits and risks of anticoagulation therapy.

© 2009-2010 Boehringer Ingelheim Corporation or an affiliated company. All rights reserved. Use of this site is subject to the terms and conditions set out in the Agreement to use the Boehringer Ingelheim Corporation and its U.S. affiliates' web sites. All content intended for U.S. residents only. Terms of Use and Privacy Policy.